The situation in ovarian cancer is less clear (recently reviewed in Serrano-Olvera et al, 2006), with contradicting results of HER2/neu expression in the prognosis of the disease and very little available data on its potential for therapeutic manipulations, prompting us to investigate HER2/neu expression and its potential consequences in ovarian cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.